Multimodal Nanosheet Artificial Antibodies for Augmented Cancer Immunotherapy
Nanosheet artificial antibodies featuring unique tripeptide assembly phases selectively bound to PD-L1 with nanomolar affinity enabling effective inhibition of the PD-1/PD-L1 signaling pathway are presented, providing an effective therapeutic strategy for cancer treatment.